Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NWBO SOMEDAY ON TV ? AMERICAN GREED !
YOUR NOT MISSING ANYTHING IMHO
THIS COULD END UP ON REALITY TV
I think what we need to do is create a document with the names and the amount of shares each person has in this company and send those multi million share account document to the company and the demand that we be updated on the trial.
how do you know the most recent investors will "pillage and dump' as you imply?
your implication is equally baseless.
And he mentioned 4-6 weeks and that was two weeks ago???
Very very interesting
I remember Michael Bigger tweeting " Now let's wait for the data" in response to someone but can't find the tweet.
Please tell me why you all keep on trusting LP ?? Please tell me
A deal with BP would have been better not only for us but also for patients .. I simply can not understand you keep believing in LP as she obviously has herself and Cognate as first priority and not Nwbo ..
If we have the goods as you all say we have, why should a BP not be interested in 50% just to pay costs ..
This deal that has been concluded with Cognate and investors, would LP never have agreed to if she did not own Cognate .. please explain me? What am I missing?
Thanks GGB. Hope you get a response from NWBO on our behalf. It is interesting that warrants were concurrently exercised bringing some needed funds. Someone must be optimistic to be exercising when the PPS is not deep in the money.
"Concurrent with the closing of the Series A Offering, the Company also exchanged previously issued warrants for the purchase of 6,686,342 shares of our Common Stock, exercisable at $0.26 per share, for Class D-1 Warrants for the purchase of 11,792,482 shares of our common stock, exercisable at $0.22 per share, and 120,590 shares of Series A Preferred Stock. Such securities are being exchanged and issued to certain investors in consideration of approximately $2,000,000 in additional investments received by the Company in this offering "
The entire premise of your long rant is that these new investors are in it for the long haul. What proof do you have of that? Maybe it's the same vultures bs but they simply have to wait a few days until the shares are available under a revised shelf. How do you know they aren't going to pillage and dump this down to new all time lows as soon as they can? It is a totally baseless hypothesis that this isn't more of the same toxic dilution, except with a slight delay.
In reality the float argument is bogus too. You don't think Cognate will sell? Are you familiar with their previous sales?
Now that is very very interesting eh??
Agreed. Investor NDAs covered (a) the existence and terms of the transaction prior to those being released in an 8k (this would include voting arrangements, etc), and (b) a separate NDA covering certain fundamental information about the trial / company.
All investors would have to sign "a". This NDA would prohibit trading until the 8k is released. NDA "b", while optional, would give long term investors comfort that the technology is compelling. The can't sell until the fundamental data is publicly available but why would they? If there is a significant therapeutic benefit, the stock is not going to stop at $0.50
...you too.
Sorry, long post! executive summary, yes but don't overlook the fact that having investors buying the offerings vs vultures is super HUGE good for longs. And Big Kudos to Flipper for pointing out that the float is much smaller than the total shares/warrants outstanding.
News Brief: The bigger guys playing in the capital markets have a HUGE advantage, esp when funding weak companies who have no highly competitive offers to raise capital. We've seen in every single offering for the last 2 years that the bloodsuckers, er funders, get 100% warrant coverage, this is a huge discount. These guys can turn around and sell all the shares and just keep the warrants; or use the warrants as safety against a run up and after selling all the shares, continue selling into shorting against the warrants. It's a huge hazard to invest in financially weak companies but the vulture funders can avoid most of the risk while getting outside rewards.
That having been said, I think it's a big misunderstanding to get pissed off about disclosure! Longs really, really, really want offerings to go into the hands of investors vs the vultures!!! Having the shares go to people who actually believe in the company and will hold the shares is an incredible benefit to us. The 'normal' funding through vulture hedge funds who specialize in quick flips put enormous downward pressure on the stock. I think the action we are seeing with buying before the offering leading to a jump and we don't immediately get slammed right down is totally because investors, not vultures have bought all of the very largely dilutional preferred shares. We can't be certain, but it does look pretty darn good from where I sit, that the stock hasn't gotten slammed at least not yet.
Big Kudos to Flipper for calling a lot of attention to this: while the total share count has gone way up, the number of shares in the float, subject to being traded every day is way less than the total. If the latest preferred offerings all stay off the market, that helps to avoid another collapse and also makes for rocket fuel if the company finally announces data that demonstrates clearly that dcvaxl works!
Thank you...I had to let some of the dream go...can’t afford it. I am holding a small position, and I still remain hopeful for the technology. GLTY
Just an observation that both Advent and Cognate appear to have 2 manufacturing locations each. One more for development and the other more for production. Cognate Bioservices has been on a recent hiring run for both Memphis and Maryland. Just an observation.
By the way DoGood, I appreciate your posts and think we are on the same side regarding NWBO. We both think they will be successful and give LP goo-gobs of credit. I just believe we should be getting the info as communicated or given a reason why. Hope i expressed myself in a respectful and non-offensive way.
If anybody understands the extra $2M investment identified in item 3.02 of the latest 8-k for the offering, please help me understand the pricing. It's a complicated mix of reducing some 6M warrants from .26 to .22, issuing 5M new warrants at .22 and issuing 120k new preferred warrants. Given that the preferred is worth $1.70, that part is only about $200k. The .04 warrant strike reduction for 6M is only worth another some $250k, and the 5M or so new warrants at .22 seem like they'd be worth well under .22 - even pricing those at .22 (and they gotta be worth far less than that) would still net out to value of under $1.5M for $2M cash. What am I missing, if anybody is curious enough to try to figure this mystery out?
Thanks Chris, but yes i had read the written testimony at least ten times. i wanted to hear if he added to or changed anything and i wanted hear his answers to any questions. i'll have to wait for the transcript. GL
New 8k: https://www.sec.gov/Archives/edgar/data/1072379/000114420417062799/tv480895_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 1, 2017
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-35737 94-3306718
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
Financing
On December 1, 2017, Northwest Biotherapeutics, Inc. (the “Company”) entered into Subscription Agreements (the “Subscription Agreements”) with certain investors. Pursuant to the Subscription Agreements, the Company agreed to issue to certain investors in a registered direct offering (the “Series A Offering”) an aggregate of 7,058,235 shares of the Company’s Series A Preferred Stock, par value $0.001 per share, at a purchase price of $1.70 per share, and two-year Class D-1 Common Stock Purchase Warrants (the “Class D-1 Warrants”) to purchase up to 70,582,351 shares of common stock at an exercise price of $0.22 per share.
Prior to this offering of Series A Preferred Stock, the Company had not issued any shares of preferred stock although 40 million such shares are authorized under the Company’s Articles of Incorporation (the “Articles”) in addition to the 450 million of shares of Common Stock authorized under the Articles.
The Series A Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance. When sufficient shares of common stock are available for issuance upon conversion, each share of Series A Preferred Stock will be convertible at the option of the holder, at any time, into a total of 10 shares of registered common stock, par value $0.001 per share, for a total of 70,582,350 shares of common stock (the equivalent of a conversion price of $0.17 per share of common stock). Shares of the Series A Preferred Stock will only receive dividends if the common stock receives dividends, and such dividends would be in the same amount, on an as-converted basis. In case of a liquidation event, if the Series A Preferred Stock is still outstanding at that time, each holder will, with respect to each Series A Preferred share owned by such holder, be entitled to a liquidation preference of either the amount paid for the Series A Preferred share or the amount that that the holder of such Series A Preferred share would have received if it had converted such share to common stock immediately prior to the liquidation event.
The Class D-1 Warrants are not currently exercisable and will become exercisable only when shares of common stock are available for issuance upon exercise.
In connection with the Series A Offering, the Company will enter into voting agreements with certain investors, in substantially the form filed as Exhibit 10.2 hereto and incorporated herein by reference.
The Series A Offering was made pursuant to the Company’s shelf registration statement on Form S-3, filed with the Securities and Exchange Commission (“SEC”) on September 23, 2016, which became effective on October 18, 2016 (File No. 333-213777), as supplemented by a prospectus supplement to be filed with the SEC.
The Company plans to use the net proceeds from the Series A Offering for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures and acquisitions of new technologies and investments.
The foregoing is only a summary of the material terms of the documents related to the Series A Offering. The foregoing description of the Series A Preferred Stock is qualified in its entirety by reference to the full text of the Certificate of Designations of Series A Preferred Stock which is filed as Exhibit 3.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The foregoing description of the Class D-1 Warrants is qualified in its entirety by reference to the Form of Class D-1 Common Stock Purchase Warrant which is filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The foregoing description of the Subscription Agreements is qualified in its entirety by reference to the Form of Subscription Agreement which is filed as Exhibit 10.3 to this Current Report on Form 8-K, which is incorporated herein by reference.
On December 4, 2017, the Company issued a press release announcing the Series A Offering. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
Concurrent with the closing of the Series A Offering, the Company also exchanged previously issued warrants for the purchase of 6,686,342 shares of our Common Stock, exercisable at $0.26 per share, for Class D-1 Warrants for the purchase of 11,792,482 shares of our common stock, exercisable at $0.22 per share, and 120,590 shares of Series A Preferred Stock. Such securities are being exchanged and issued to certain investors in consideration of approximately $2,000,000 in additional investments received by the Company in this offering
The new warrants and Series A Preferred Stock described in this Item 3.02 will be issued pursuant to the exemption from the registration requirements afforded by Section 3(a)(9) of the Securities Act.
Item 3.03 Material Modification to Rights of Security Holders.
The discussion in Items 1.01 and 5.03 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 5.03.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Certificate of Designations of Series A Preferred Stock
The discussion in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 5.03.
On December 1, 2017, the Company filed the Certificate of Designations of Series A Preferred Stock (the “Series A Certificate of Designations”) with the Secretary of State of the State of Delaware, setting forth the terms of the Series A Preferred Stock. The Series A Certificate of Designations, effective as of December 1, 2017, created out of the authorized and unissued shares of preferred stock of the Company, the Series A Preferred Stock, consisting of 15,000,000 shares, par value $0.001 per share and established the rights, preferences and privileges thereof. A copy of the Series A Certificate of Designations is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The foregoing does not purport to be a complete description of the Series A Certificate of Designations and is qualified in its entirety by reference to the full text of the Series A Certificate of Designations.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
3.1 Certificate of Designations of Series A Preferred Stock.
10.1 Form of Class D-1 Common Stock Purchase Warrant.
10.2 Form of Voting Agreement.
10.3 Form of Subscription Agreement.
99.1 Press Release issued December 4, 2017.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NORTHWEST BIOTHERAPEUTICS, INC.
Date: December 7, 2017 By: /s/ Linda Powers
Name: Linda Powers
Title: Chief Executive Officer and Chairman
And how does this trading pattern tell you this? Maybe it is a short just pumping up the price so he can sell more short in the morning?
No. Not at all, DoGood_DoWell.
LP, in February, already provided an update on the P3 OS threshold and the approval process (specifically datalock) with completion estimates ("several months" for OS events and "multi-months" for datalock). Now, after she puts this info out there, a lawyer advises her to not to provide further data? Are you suggesting that sometime after the February PR, a lawyer directed LP to clam up? If so, that can't be good.
I am not a lawyer (don't know if you are) but I question whether an attorney has anything to do with this. We cannot keep speculating as to why we shareholders (technically part-owners of the company) are no getting the basic and fundamental info when LP, through a PR, told us when to expect this info! LP should give us the info or tell us why she can't before she asks us to provide shares for possibly more dilution!
Regarding Cofer: the internal investigative report was to be done in 90 days. It's been 2-3 years. The screen halt was in place for approx 2.5 years but has been lifted. We still don't know what that was about. Do you think management should be able to spend whatever they want with no transparency and accountability? The results (in terms of PPS and MC) of the $ billion they are ready raised and spent strongly suggest no!
mapman1010,
check this link out. This should work. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588046.htm
Right because it could never be someone unloading a position. Why is it always some new investor building a large position? Not a lot of folks trolling the OTC to build large long positions. It would only take 50k to buy a ton!
I have seen similar pattern in couple of other stocks I used to follow . The reason given there was that when market is expecting news anyday, the day traders and some investors buy before the end of the day so that they don’t miss out on gap up if there is news AH or premarket
Tells me there is Accumulation of stock by someone(s).
The problem with your position is focusing too much with the exception to a fair disclosure and not the rule itself as it affects any shareholder owed a fiduciary duty and reasonable timely 8k disclosure. It would be a real problem, if one goes around one day telling shareholders public statements, then selectively finds preferred shareholders a short time later to arm them with opposite statements of intent without telling the prior earlier shareholder of the modification. Not saying that was done here. In other words, you are focusing on the preferred shareholder and not on the common shareholder. IMO. In other words, if it is material when you told retail, is it then not still material when you didn't tell them that info you gave them that they are still relying upon to trade is now bunk? Particularly when you armed someone else with the change? Not saying anything of the kind happened here. In my opinion, that would be a problem.
LOL. Absolutely, happy to add what I can.
It's actually an area of law (public securities, particularly disclosure rules) that I need to brush up on if I'm going to dabble in this world.
Thanks to you and everyone else on this board for adding to the discussion, without which I would have never learned enough to feel comfortable placing an educated bet on NWBO.
I have noticed that trading pattern too over the last little while.
So what does it tell you??
I agree, very very interesting trading action.
Selling in the AM
Buying in the PM.
barcode27,
I can't open those links. Would you mind sharing a summary opinion of what you see as interesting? TIA and best wishes.
Thanks for taking the effort to add your $200.00 ($0.02 inflated to unfair but normal legal billing rates - just kidding) to this discussion.
So if Linda were receiving advice on what to do, should she listen to you or to Cofer? Or her lawyers?
A few recent filings in the Chardan case. The email chains filed as exhibits are an interesting read.
https://drive.google.com/file/d/1vuNptgxlCQpCailtVtfntlUPEQM4tu2f/view?usp=drivesdk
https://drive.google.com/file/d/1v_5m27QZxAA-iv-j1spnBs4HG_xwCePe/view?usp=drivesdk
https://drive.google.com/file/d/1GI5ieLt3kYj5UvBT-FVcPtatnVhcEBUf/view?usp=drivesdk
https://drive.google.com/file/d/1OgTFIACEg_RLBh5VR6MTNfBJD3foA73_/view?usp=drivesdk
https://drive.google.com/file/d/1GshRkREsN1-tAchSMSVUStieMMaS2f2f/view?usp=drivesdk
manibiotech,
In NWBO's position everything shared is considered self promotion by those who want nothing good said about their products by them. They have a skeleton staff and rely on the doctors at UCLA and occasionally Dr. Bosch to explain the science to the point of piquing interest but not giving away too much about the recipes. Dr. Bosch is The Expert in my opinion when it comes to Direct and Dr. Linda Liau is the expert on L with additional understanding of mechanisms of action and improvements added into by others along the way including what the Germans and Cognate were able to do to improve the basic formula and understanding of MO. As the understanding of DC subsets evolved I believe the quest to improve upon L Sub Rosa began and was done legitimately based on the looseness of the original IND. This may be one of the reasons we have been waiting so long for results. Optimizing DC technology truly is an art that requires a deep understanding of the various more specific functions of DC subsets especially in the use of L. Direct seemed to kind of leap frog the need for this a little bit but I believe their study of Direct brought them to a better understanding of how to improve Direct and L as well. This became gradually very clear to me a little over 2 years ago. To answer your question more directly, not everything that I have read in the public domain is well knitted together there or well understood as common knowledge. I believe NWBO has good reason to keep it that way to protect what advantage they still have in their understanding of DCs over competitors who would now like to catch up while NWBO apparently waits on results. Best wishes.
I often tell my clients that 9 times out of 10 the law and common sense align, but it's that one other time that is the reason I am employed.
Securities is not my primary area of expertise, but I believe the company might not be obligated to correct the disclosure in the prior example (10 days 100 days).
https://www.kattenlaw.com/files/upload/Disclosure_Duties_Arising_Under_Section_10B_When_To_Correct_Or_Update.pdf
The first paragraph under Section I, Duty to Disclose, is particularly informative. See below
There will be no news before voting .. LP have put us in a situation where we can vote yes to keep going and hoping or vote no and go bankrupt ..
She probably didnt have so many possibilities, but she could have given BP 50% of the company "free for charge" if they just paid costs .. and we would have been better off economically plus we would have had a BP to back us with expatice and people who knew about FDA better that LP + we would not need further dilution .. But then LP and Cognate wouldn't have so many shares.. just saying..
You do not remember my positions correctly.
I think it would be very, very interesting
That certainly is very interesting
If they managed to get blinded interim data published in any journal of that caliber, that would b a Christmas miracle! Only way I can see that happening is if they managed to turn the blinded outcome data into some mechanistically-relevant study that is not dependent on knowing treatment condition (e.g., immune changes as predictors of PFS or OS).
Chinatown1980, I don't think you and I are on the same page. If I remember your positions correctly, you think LP is a crook and NWBO is a scam. I don't. I think the science is legitimate and give Linda (who I hold in high esteem) credit for getting us this far. Furthermore, I think she is taking what she thinks is the safest/easiest route to the finish line. I really support her and the company. I want to approve an increase of authorized shares but that requires additional info as I laid out previously.
No creditable manager/shareholder would approve this, imho, without this info.
Volume is unconvincing and not sure if we close in the green, but I'll take this any day over closing near LOD! At least there is clear sign of buying demand to at least equal the random attrition sellers who have to sell for xmas presents etc.
I'm cautious but hopeful that we get some positive news and don't have to sit around this level for a long time just hoping that nobody decides to test how far they can push this down.
Look, if you (pretend you are a company) told me today, a material report would be ready in 10 days, but in 5 days you had a different investor sign an NDA and told him the material report would not be ready for 100 days.,..there is a problem. IMO.
Not saying that was done here.
RegFD is about fair disclosure, and there is an NDA exception. I'm asking if you're asserting an exception to that exception because you have researched this technical/legal question or because you have personal experience to know this or is it only because by your own common sense you have concluded that case should be an exception to the exception that allows "unfair" disclosure to specific limited investors as long as they have signed NDAs.
VuBru, SAGE jumped 70% today on release of some positive news on their trial data. Publication of interim blinded data might be possible tomorrow, imo.
Point taken. I already planned to write to the company and have started a draft. I'll have it done within a few days and will e- and snail- mail it directly there after. I don't think it will matter but I do think its my/our responsibility to let them know.
The web is a very dark place
Followers
|
1620
|
Posters
|
|
Posts (Today)
|
174
|
Posts (Total)
|
689572
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |